Our Work

Since the beginning of the COVID-19 pandemic in 2020 policymakers have consulted epidemiologists and economists to determine the best course of action.

A symposium co-hosted by HBHI and the Hopkins Economics of Alzheimer's Disease and Services Center covers the ramifications of the approval of controversial Alzheimer's Disease drug Aduhelm for patients enrolled in approved clinical trials.

Join our distinguished panel of public health experts and vaccine industry executives for an engaging discussion examining every aspect of the COVID-19 vaccine from discovery to manufacturing to delivery.